当前位置： SCI文献检索 > PROSTATE CANCER AND PROSTATIC DISEASES期刊下所有文献 > Localized prostate cancer and 30 years of follow-up in a population-based setting.

Localized prostate cancer and 30 years of follow-up in a population-based setting.

Abstract：

:Some patients with a histopathological diagnosis of prostate cancer have a tumour that behaves benignly during long-term follow-up. The proportion of patients with such a tumour is unknown, as is the fraction who die of prostate cancer between 10 and 20 y of follow-up. All men aged 45-84 y obtaining a diagnosis of prostate cancer between 1965 and 1993 and being reported to the Finnish Cancer Registry were observed. Death was recorded as caused by prostate cancer or not. We identified 11,500 men with localized prostate cancer and in this group the disease-specific survival rate reached a plateau at approximately 30% after 23 y of follow-up. In the same cohort, 5% of the patients died of prostate cancer during years 11-20 of follow-up. During the observation period, somewhat less than half of the patients with localized prostate cancer who died, died of the disease. This proportion decreased with duration of follow-up. In conclusion, early aggressive therapy for localized prostate cancer is unnecessary, in terms of survival, for those with a benignly behaving tumour (about 30% in this series) or who die of intercurrent disease (about 50% in this series). Such therapy may, however, prolong life for the patients and may cure the patients that die of prostate cancer after more than 10 y follow-up. Prostate Cancer and Prostatic Diseases (2000) 3, 37-42

journal_name

Prostate Cancer Prostatic Dis

journal_title

Prostate cancer and prostatic diseases

authors

Adolfsson J,Oksanen H,Salo JO,Steineck G

doi

10.1038/sj.pcan.4500395

subject

Has Abstract

pub_date

2000-07-01 00:00:00

pages

37-42

issue

1

eissn

1365-7852

issn

1476-5608

pii

4500395

journal_volume

3

pub_type

杂志文章

相关文献

PROSTATE CANCER AND PROSTATIC DISEASES文献大全
  • Comparison of outcomes after TURP versus photoselective vaporization of the prostate with respect to trainee involvement utilizing ACS NSQIP.

    abstract：BACKGROUND:Large multicenter studies comparing outcomes between TURP and photoselective vaporization of the prostate (PVP) are sparse, with no studies having compared the influence of trainee involvement on these outcomes. Our objectives were to assess 30-day outcomes after TURP and PVP with respect to trainee involvem...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章,多中心研究

    doi：10.1038/pcan.2014.13

    authors： Olcese SP,Derosa R,Kern SQ,Lustik MB,Sterbis JR,McMann LP

    更新日期：2014-09-01 00:00:00

  • Histological characteristics of the index lesion in whole-mount radical prostatectomy specimens: implications for focal therapy.

    abstract：:It has been suggested that in multifocal prostate cancer (PCa), focal therapy to the largest (index) lesion is sufficient, because secondary non-index lesions are unlikely to contribute to disease progression. In this study, the role of PCa focality in selecting men for focal therapy was evaluated. A histopathological...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/pcan.2010.16

    authors： Karavitakis M,Winkler M,Abel P,Livni N,Beckley I,Ahmed HU

    更新日期：2011-03-01 00:00:00

  • Plasma cell-free DNA-based predictors of response to abiraterone acetate/prednisone and prognostic factors in metastatic castration-resistant prostate cancer.

    abstract：BACKGROUND:The combination of abiraterone acetate and prednisone (AA/P) is used to treat metastatic prostate cancer, but molecular predictors of treatment response are not well elucidated. We evaluated plasma circulating tumor DNA- (ctDNA-) based copy number alterations (CNAs) to determine treatment-related predictive ...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/s41391-020-0224-4

    authors： Du M,Tian Y,Tan W,Wang L,Wang L,Kilari D,Huang CC,Wang L,Kohli M

    更新日期：2020-12-01 00:00:00

  • Characterization of expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in prostate cancer cell lines.

    abstract：:Stromal expression of some matrix metalloproteinases (MMPs) has been associated with increasing tumour burden in prostate cancer. We investigated the expression of mRNA (by RT-PCR) and protein (by zymography and western blotting) of MMPs and endogenous inhibitors (tissue inhibitors of metalloproteinases, TIMPs) in two...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/sj.pcan.4500609

    authors： Daja MM,Niu X,Zhao Z,Brown JM,Russell PJ

    更新日期：2003-01-01 00:00:00

  • The role of candidate genetic polymorphisms in the etiology of prostate cancer.

    abstract：:Prostate cancer appears to result from complex interactions among genetic, endocrine and environmental factors. Identification of risk factors for development and progression of prostate cancer is needed. This will allow researchers to design strategies to reduce the morbidity and mortality from this cancer and to ide...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/sj.pcan.4500471

    authors： Neuhausen SL

    更新日期：2000-12-01 00:00:00

  • Invasion of bladder neck after radical prostatectomy: one definition for different outcomes.

    abstract：:The aim of the study was to evaluate factors of progression after radical prostatectomy in patients with bladder neck invasion (BNI). From 1988 to 2006, 1395 patients underwent radical prostatectomy, 120 (8.6%) had microscopic BNI (pT4 N0, TNM 2002). Group 1 was defined as BNI alone, group 2 as BNI plus extracapsular ...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/sj.pcan.4501009

    authors： Rodriguez-Covarrubias F,Larré S,Dahan M,De La Taille A,Allory Y,Yiou R,Vordos D,Hoznek A,Abbou CC,Salomon L

    更新日期：2008-01-01 00:00:00

  • SELECT: the Selenium and Vitamin E Cancer Prevention Trial: rationale and design.

    abstract：:Prostate cancer is the commonest non-skin malignancy in the United States and has a substantial mortality rate despite the use of PSA-based screening. Furthermore, therapy for prostate cancer by surgery, radiotherapy or hormonal manipulation carries a significant risk of treatment-related morbidity. Recent analysis of...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/sj.pcan.4500412

    authors： Klein EA,Thompson IM,Lippman SM,Goodman PJ,Albanes D,Taylor PR,Coltman C

    更新日期：2000-11-01 00:00:00

  • Approaches to urinary detection of prostate cancer.

    abstract：BACKGROUND:Prostate cancer is the most common cancer in American men that ranges from low risk states amenable to active surveillance to high-risk states that can be lethal especially if untreated. There is a critical need to develop relatively non-invasive and clinically useful methods for screening, detection, progno...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章,评审

    doi：10.1038/s41391-019-0127-4

    authors： Eskra JN,Rabizadeh D,Pavlovich CP,Catalona WJ,Luo J

    更新日期：2019-09-01 00:00:00

  • Patient-reported quality of life progression in men with prostate cancer following primary cryotherapy, cyberknife, or active holistic surveillance.

    abstract：BACKGROUND:Technological advancements have led to the success of minimally invasive treatment modalities for prostate cancer such as CyberKnife and Cryotherapy. Here, we investigate patient-reported urinary function, bowel habits, and sexual function in patients following CyberKnife (CK) or Cryotherapy treatment, and c...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/s41391-017-0004-y

    authors： Werneburg GT,Kongnyuy M,Halpern DM,Salcedo JM,Kosinski KE,Haas JA,Schiff JT,Corcoran AT,Katz AE

    更新日期：2018-09-01 00:00:00

  • A functional polymorphism in the CYR61 (IGFBP10) gene is associated with prostate cancer risk.

    abstract：BACKGROUND:CYR61 (cysteine-rich protein 61, also named IGFBP10) is a secreted signaling molecule that promotes angiogenesis and tumor growth. The goal of this study is to determine whether a functional polymorphism in the promoter region of the CYR61 gene (rs3753793) is associated with prostate cancer (PCa) risk and ge...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/pcan.2012.41

    authors： Tao L,Chen J,Zhou H,Qin C,Li P,Cao Q,Li J,Ju X,Zhu C,Wang M,Zhang Z,Shao P,Yin C

    更新日期：2013-03-01 00:00:00

  • Prediction of extraprostatic extension by MRI tumor contact length: difference between anterior and posterior prostate cancer.

    abstract：BACKGROUND:Tumor contact length (TCL) is defined as the extent of contact between prostate cancer and the prostatic capsule, and its predictive value for microscopic extraprostatic extension (EPE) has been reported. However, the impact of the zonal origin (anterior or posterior tumor) of the tumor on the diagnosis of E...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/s41391-019-0136-3

    authors： Matsumoto K,Akita H,Narita K,Hashiguchi A,Takamatsu K,Takeda T,Kosaka T,Mizuno R,Kikuchi E,Oya M,Jinzaki M

    更新日期：2019-12-01 00:00:00

  • Influence of serum testosterone on urinary continence and sexual activity in patients undergoing radical prostatectomy for clinically localized prostate cancer.

    abstract：:The aim of the present study was to evaluate how serum testosterone level (T) can affect urinary continence and erectile function in patients undergoing radical prostatectomy (RP). We included 257 patients with clinically localized prostate cancer, those who had filled out preoperative quality of life questionnaires (...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/pcan.2010.4

    authors： Gacci M,Corona G,Apolone G,Lanciotti M,Tosi N,Giancane S,Masieri L,Serni S,Maggi M,Carini M

    更新日期：2010-06-01 00:00:00

  • Testosterone replacement therapy for late onset hypogonadism: what is the risk of inducing prostate cancer?

    abstract：:Prescription sales of testosterone have risen considerably over the last decade and are likely to continue to grow as further preparations become available. Testosterone promotes existing prostate cancer; however, concern does exist as to whether or not testosterone therapy induces prostate cancer. The aim of this art...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章,评审

    doi：10.1038/sj.pcan.4500839

    authors： Gould DC,Kirby RS

    更新日期：2006-01-01 00:00:00

  • Exposure to direct-to-consumer advertising is associated with overestimation of benefits regarding ultrahypofractionated radiation therapy for prostate cancer.

    abstract：BACKGROUND:While direct-to-consumer (DTC) medical advertising can provide useful information, it also risks oversimplification and being misleading. For an abbreviated prostate cancer treatment regimen called "ultrahypofractionation" (UHF), advertising has been used for CyberKnife (CK), a common delivery system for ste...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/s41391-020-0234-2

    authors： Caputo JM,Lee HJ,Chiles B,Hyams ES

    更新日期：2020-12-01 00:00:00

  • Fatigue in hormone-naïve prostate cancer patients treated with radical prostatectomy or definitive radiotherapy.

    abstract：:Chronic fatigue (CF) is a distressing symptom that follows cancer treatment; however, it has rarely been studied in hormone-naïve prostate cancer survivors after radical prostatectomy (RP) or definitive radiotherapy (RAD). We investigated CF in prostate cancer survivors after RP or RAD as monotherapy and explored asso...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/pcan.2009.61

    authors： Kyrdalen AE,Dahl AA,Hernes E,Cvancarova M,Fosså SD

    更新日期：2010-06-01 00:00:00

  • Frequency of impalpable prostate adenocarcinoma and precancerous conditions in Greek male population: an autopsy study.

    abstract：:A series of 212 prostate specimens of men dead between August 2002-August 2004, have been sectioned in consecutive autopsies and subjected to whole mount analysis in purpose to determine the epidemiology of impalpable prostate cancer in Greece. Impalpable prostate carcinomas were found in 40 cases (18.8%) most in the ...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/sj.pcan.4500847

    authors： Stamatiou K,Alevizos A,Perimeni D,Sofras F,Agapitos E

    更新日期：2006-01-01 00:00:00

  • A randomized, phase II study of pazopanib in castrate-sensitive prostate cancer: a University of Chicago Phase II Consortium/Department of Defense Prostate Cancer Clinical Trials Consortium study.

    abstract：BACKGROUND:Intermittent androgen suppression (IAS) is an increasingly popular treatment option for castrate-sensitive prostate cancer. On the basis of previous data with anti-angiogenic strategies, we hypothesized that pan-inhibition of the vascular endothelial growth factor receptor using pazopanib during the IAS off ...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1038/pcan.2011.49

    authors： Ward JE,Karrison T,Chatta G,Hussain M,Shevrin D,Szmulewitz RZ,O'Donnell PH,Stadler WM,Posadas EM

    更新日期：2012-03-01 00:00:00

  • Gyrus bipolar electrovaporization vs transurethral resection of the prostate: a randomized prospective single-blind trial with 1 y follow-up.

    abstract：:The Gyrus system uses bipolar electrocautery with saline irrigation to vaporize prostatic tissue and is compared to transurethral resection of the prostate (TURP) in a randomized prospective study with 1 y follow-up. Outcomes measured were fluid absorption, blood loss, period of catheterization, hospital stay, symptom...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1038/sj.pcan.4500631

    authors： Dunsmuir WD,McFarlane JP,Tan A,Dowling C,Downie J,Kourambas J,Donnellan S,Redgrave N,Fletcher R,Frydenberg M,Love C

    更新日期：2003-01-01 00:00:00

  • Prostate cancer detection and tumor characteristics in men with multiple biopsy sessions.

    abstract：PURPOSES:To address prostate cancer (PCa) detection with respect to the number of biopsy sessions performed, to identify risk factors for detection after a negative biopsy, and to analyze the clinical characteristics of the detected tumors. SCOPE:Only biopsied men (sextant) were included. A total of 1011 biopsy sessio...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/sj.pcan.4500730

    authors： Lujan M,Paez A,Santonja C,Pascual T,Fernandez I,Berenguer A

    更新日期：2004-01-01 00:00:00

  • Association between metabolic syndrome, diabetes mellitus and prostate cancer risk.

    abstract：BACKGROUND:The worldwide incidence of diabetes mellitus is rapidly increasing. There is recent interest in the influence of glucose metabolism on oncogenesis. We investigated the role of diabetes mellitus and the metabolic syndrome (MS) on prostate cancer development. METHODS:This study consisted of 11 541 men with co...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/pcan.2012.54

    authors： Lawrence YR,Morag O,Benderly M,Boyko V,Novikov I,Dicker AP,Goldbourt U,Behar S,Barchana M,Wolf I

    更新日期：2013-06-01 00:00:00

  • The microbiome in prostate inflammation and prostate cancer.

    abstract：BACKGROUND:The human microbiome may influence prostate cancer initiation and/or progression through both direct and indirect interactions. To date, the majority of studies have focused on direct interactions including the influence of prostate infections on prostate cancer risk and, more recently, on the composition of...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章,评审

    doi：10.1038/s41391-018-0041-1

    authors： Porter CM,Shrestha E,Peiffer LB,Sfanos KS

    更新日期：2018-09-01 00:00:00

  • Use of bisphosphonates can dramatically improve pain in advanced hormone-refractory prostate cancer patients.

    abstract：INTRODUCTION:Approximately 85% of patients who die from prostate cancer present the spread of bone metastases. Even though the radiological appearance of such metastases is osteoblastic, it is now known that these lesions coexist in their microenvironment with blastic and lytic lesions. The process always begins with b...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/sj.pcan.4500752

    authors： Rodrigues P,Hering F,Campagnari JC

    更新日期：2004-01-01 00:00:00

  • Initial assessment of safety and clinical feasibility of irreversible electroporation in the focal treatment of prostate cancer.

    abstract：BACKGROUND:To evaluate the safety and clinical feasibility of focal irreversible electroporation (IRE) of the prostate. METHODS:We assessed the toxicity profile and functional outcomes of consecutive patients undergoing focal IRE for localised prostate cancer in two centres. Eligibility was assessed by multi-parametri...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/pcan.2014.33

    authors： Valerio M,Stricker PD,Ahmed HU,Dickinson L,Ponsky L,Shnier R,Allen C,Emberton M

    更新日期：2014-12-01 00:00:00

  • Impact of age on exposure to oral antiandrogen therapies in clinical practice.

    abstract：BACKGROUND:Oral antiandrogen therapies are predominantly used in older men, but real-life studies evaluating the impact of age on pharmacokinetic exposure are lacking. This study aims to evaluate the impact of age on the pharmacokinetic profiles of abiraterone acetate and enzalutamide in clinical practice. PATIENTS AN...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/s41391-018-0096-z

    authors： Crombag MBS,van Nuland M,Bergman AM,Rosing H,Schellens JHM,Huitema ADR,Beijnen JH

    更新日期：2019-03-01 00:00:00

  • Time course of late rectal toxicity after radiation therapy for prostate cancer.

    abstract：:Rectum and bladder are the crucial organs at risk for curative radiation therapy of localized prostate cancer. We analyzed the incidence, profile and time course of late rectal radiation toxicity. A total of 320 patients with T1-3 prostate cancer were treated with three-dimensional conformal radiation therapy (3D-CRT)...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/pcan.2009.56

    authors： Odrazka K,Dolezel M,Vanasek J,Vaculikova M,Zouhar M,Sefrova J,Paluska P,Vosmik M,Kohlova T,Kolarova I,Macingova Z,Navratil P,Brodak M,Prosvic P

    更新日期：2010-06-01 00:00:00

  • Potential of intermittent hormone therapy for M+ and M0 prostate cancer patients.

    abstract：:Increasingly animal and clinical studies suggest that intermittent therapy may improve the duration of hormone dependence in patients with prostate cancer. However there remains uncertainty as to optimal duration of treatment and level of prostate-specific antigen (PSA) before treatment is restarted. The aim of this s...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/sj.pcan.4500483

    authors： Oliver RT,Farrugia D,Ansell W,Williams G,Chinegwundoh F

    更新日期：2000-12-01 00:00:00

  • MRI in active surveillance: a critical review.

    abstract：INTRODUCTION:Recent technological advancements and the introduction of modern anatomical and functional sequences have led to a growing role for multiparametric magnetic resonance imaging (mpMRI) in the detection, risk assessment and monitoring of early prostate cancer. This includes men who have been diagnosed with lo...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章,评审

    doi：10.1038/s41391-018-0077-2

    authors： Stavrinides V,Giganti F,Emberton M,Moore CM

    更新日期：2019-03-01 00:00:00

  • Cost-effectiveness analysis of Abiraterone Acetate versus Docetaxel in the management of metastatic castration-sensitive prostate cancer: Hong Kong's perspective.

    abstract：BACKGROUND:Several randomized control trials (RCTs) have showed that adding either abiraterone acetate (AA) or docetaxel (D) to androgen-deprivation therapy (ADT) improves survival of metastatic castration-sensitive prostate cancer patients (mCSPC). Yet, the cost-effectiveness of these treatment options has not been fu...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/s41391-019-0161-2

    authors： Chiang CL,So TH,Lam TC,Choi HCW

    更新日期：2020-03-01 00:00:00

  • Cardiac biomarkers in patients with prostate cancer and cardiovascular disease receiving gonadotrophin releasing hormone agonist vs antagonist.

    abstract：BACKGROUND:Gonadotrophin releasing hormone (GnRH) agonists and antagonists reduce testosterone levels for the treatment of advanced and metastatic prostate cancer. Androgen deprivation therapy (ADT) is associated with increased risk of cardiovascular (CV) events and CV disease (CVD), especially in patients with preexis...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/s41391-020-0264-9

    authors： Margel D,Ber Y,Peer A,Shavit-Grievink L,Pinthus JH,Witberg G,Baniel J,Kedar D,Rosenbaum E

    更新日期：2020-07-31 00:00:00

  • Histopathological findings after radiofrequency (RITA) treatment for prostate cancer.

    abstract：:Radiofrequency interstitial tumor ablation (RITA) is a thermal ablation method that uses needles and low radiofrequency (RF) energy. The aim of our study was to evaluate the histopathology of thermal lesions induced by RF energy delivered interstitially in prostate cancer patients who subsequently underwent prostatect...

    journal_title：Prostate cancer and prostatic diseases

    pub_type： 杂志文章

    doi：10.1038/sj.pcan.4500877

    authors： Patriarca C,Bergamaschi F,Gazzano G,Corrada P,Ordesi G,Zanitzer L,Di Pasquale M,Giunta P,Campo B

    更新日期：2006-01-01 00:00:00